Bayer Quickens Pace Of Polymers IPO, Other Non-Core Businesses Next?
This article was originally published in Scrip
You may also be interested in...
Despite Bayer AG's third quarter earnings call being heavily dominated by talk of the company's ongoing Monsanto acquisition and its recent deconsolidation of material science company Covestro, Xarelto stood out as the hot topic within the German firm's pharma division.
The European Commission has extended the indications for Janssen’s Tremfya to include psoriatic arthritis, and those for BMS’s Opdivo to include gastroesophageal cancer.
Denmark’s biotech Genmab has dropped the AXL targeted antibody-drug conjugate, enapotamab vedotin from early clinical development, and is focusing its resources on other therapeutic programs.